Adalimumab-Aacf
Payments companies reported to CMS as associated with Adalimumab-Aacf. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Adalimumab-Aacf, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Adalimumab-Aacf
These are the largest totals companies reported as associated with Adalimumab-Aacf. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sahdev Saharan | Tracy, CA | Rheumatology | $105.85 |
| Anthony Padula | Walnut Creek, CA | Rheumatology | $98.66 |
| David Wu | Walnut Creek, CA | Rheumatology | $98.65 |
| Adam Kreitenberg | Tarzana, CA | Rheumatology | $95.78 |
| Leonard Kane | Frederick, MD | Gastroenterology (Internal Medicine) | $74.11 |
| Stephen Meyerhuber | Catonsville, MD | Anesthesiology | $72.68 |
| Atul Agrawal | Antioch, CA | Rheumatology | $63.18 |
| Tony Makhlouf | Simi Valley, CA | Rheumatology | $63.03 |
| Israel Crespo | Tampa, FL | Gastroenterology (Internal Medicine) | $62.02 |
| Angel Rosario | Tampa, FL | Gastroenterology (Internal Medicine) | $62.01 |
Prescribed Adalimumab-Aacf?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.